At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 87 enrolled
Drug / intervention
LOXO-305drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
In Brief
A Phase 2 clinical trial evaluating LOXO-305 for Leukemia, Lymphoid and 6 related conditions. Completed, enrolled 87 participants across 22 sites.
Detailed Summary
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Leukemia, Lymphocytic, Chronic, B-Cell
CountriesChina
CollaboratorsLoxo Oncology, Inc.
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartMay 2021
Primary CompletionApr 2023
Study CompletionDec 2025
TodayJul 2026
First PostedApr 19, 2021
Enrollment StartMay 14, 2021
Primary CompletionApr 10, 2023
Study CompletionDec 29, 2025
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 5.2 years ago
Interventions
LOXO-305drug
Administered orally.